Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for copd
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
. BRONCUS = Bronchitis Randomized on NAC Cost-Utility Study; CI = confidence interval; COPD = chronicobstructivepulmonarydisease; ISOLDE = Inhaled Steroids in ObstructiveLungDisease in Europe; LHS = Lung Health Study; LHS2 = Lung Health Study 2; SUMMIT = Study to Understand Mortality and Morbidity; TORCH = Toward a Revolution in COPD Health; UPLIFT = Understanding Potential Long-Term Impacts on Function with Tiotropium. Figure 3. ( A ) Effect of… Figure 3. ( A ) Effect of ICS-containing therapies (...) on the rate of decline in… Figure 3. ( A ) Effect of ICS-containing therapies on the rate of decline in FEV 1 . The center of the diamond indicates the point estimate and the width is the 95% confidence interval (CI). ( B ) Effect of inhaled LABD therapy on the rate of decline in FEV 1 . The center of the diamond indicates the point estimate and the width is the 95% CI. COPD = chronicobstructivepulmonarydisease; ICS = inhaled corticosteroid; ISOLDE = Inhaled Steroids in ObstructiveLungDisease
and evaluation of the NHSScotland COPD Support Service, which comprises a web app to support remote and self-management of high-risk patients with ChronicObstructivePulmonary Disorder (COPD). 1 The local trial and evaluation was carried out by NHS Greater Glasgow and Clyde (NHS GG&C). COPD is a collection of lungdiseases including chronic bronchitis, emphysema and chronicobstructiveairwaysdisease. 2 People with COPD have difficulties breathing. The web app is intended to promote remote and self (...) of the pathway. References 1. NHSScotland COPD Support Service. NHSScotland COPD Support Service [online]. 2020 [cited 2021 Jan 21]; Available from: https://support.nhscopd.scot/ 2. NHS Inform. Chronicobstructivepulmonarydisease [online]. 2019 [cited 2021 Jan 21]. Available from: https://www.nhsinform.scot/illnesses-and-conditions/lungs-and- airways/copd/chronic-obstructive-pulmonary-disease Acknowledgment of professional commentators and fact checking Professional commentary was provided
Disease) trial in chronicobstructivepulmonarydisease (COPD) ( ), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause mortality compared with glycopyrrolate/formoterol fumarate (GFF). However, 384 of 8,509 patients were missing vital status at Week 52 in the original analyses. Objectives: To assess the robustness of the ETHOS mortality findings after additional data retrieval for patients missing Week 52 vital status in the original analyses (...) Free PMC article. No abstract available. References World Health Organization Global health estimates 2016: deaths by cause, age, sex, by country and by region 2000–2016 Geneva, Switzerland: World Health Organization; 2018[updated 2019 Apr 11]. Available from: Global Initiative for ChronicObstructiveLungDisease 2020 report: global strategy for the diagnosis, management and prevention of COPD Fontana, WI: Gold Initiative for ChronicObstructiveLungDisease; 2020[updated 2020 Mar 17]. Available
Formoterol fumarate dihydrate/glycopyrronium/budesonide (Trixeo Aerosphere) - adult patients with moderate to severe chronicobstructivepulmonarydisease (COPD) Published 08 February 2021 1 Product update SMC2321 formoterol fumarate dihydrate / glycopyrronium / budesonide 5mcg/7.2mcg/160mcg pressurised inhalation, suspension (Trixeo® Aerosphere) AstraZeneca 15 January 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC (...) executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission formoterol fumarate dihydrate / glycopyrronium / budesonide (Trixeo® Aerosphere) is accepted for restricted use within NHSScotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronicobstructivepulmonarydisease (COPD) who are not adequately treated by a combination
Share Permalink Copy Page navigation Eur Heart J Actions . 2020 Nov 19;ehaa793. doi: 10.1093/eurheartj/ehaa793. Online ahead of print. Association of β-blocker use with survival and pulmonary function in patients with chronicobstructivepulmonary and cardiovascular disease: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union (...) with chronicobstructivepulmonary and cardiovascular disease: a systematic review and meta-analysis Yan-Li Yang et al. Eur Heart J . 2020 . Show details Display options Display options Format Eur Heart J Actions . 2020 Nov 19;ehaa793. doi: 10.1093/eurheartj/ehaa793. Online ahead of print. Authors , , , , , Affiliations 1 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Dong
The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China. PMID: 32907384 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Objective: To investigate the effects of a mobile health smartphone application to support self-management programmes on quality of life, self-management behaviour and exercise and smoking cessation behaviour in patients with chronicobstructivepulmonarydisease (COPD). Design: A randomised controlled, single-blind (...) participants' exercise and smoking cessation behaviour. Conclusions: The mobile health smartphone application to support self-management programmes was effective in improving health-related quality of life and self-management behaviour in patients with COPD. Trial registration: This study was registered in Chinese clinicaltrials.gov. Keywords: Chronicobstructivepulmonarydisease; mobile health application; randomised control trial; self-management. Similar articles McCabe C, McCann M, Brady AM. McCabe C
pulmonarydisease (COPD) are chronic, progressive, and ultimately fatal, diseases of the lungs. Emphysema is one of two conditions that are classed as COPD, the other being chronic bronchitis. Emphysema can exist without chronic bronchitis as a distinct respiratory condition. Patients with COPD can have predominantly emphysema, predominantly chronic bronchitis, or both. Chronicobstructivepulmonarydisease is the second most common lungdisease in the UK. Treatments for emphysema/COPD include lifestyle (...) Apr 23]; Available from: https://www.mayoclinic.org/diseases-conditions/pneumothorax/symptoms-causes/syc- 20350367. 4. British Lung Foundation. COPD (chronicobstructivepulmonarydisease): emphysema. 2020 [cited 2020 Apr 23]; Available from: https://www.blf.org.uk/support-for- you/copd/emphysema. 5. Cetti EJ, Moore AJ, Geddes DM. Collateral ventilation. Thorax. 2006;61(5):371-3. 6. MedlinePlus. Subcutaneous emphysema. 2020 [cited 2020 May 07]; Available from: https://medlineplus.gov/ency/article
rehabilitation for patients with COPD: a randomised controlled trial , , , , , , , , , , , Affiliations Expand Affiliations 1 Laboratory of RespiratoryDiseases and Thoracic Surgery (BREATHE), Department of ChronicDiseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium. 2 University Pitágoras UNOPAR, Department of Rehabilitation Sciences, Londrina, Brazil. 3 Both authors contributed equally. 4 Monash University, Department of Physiotherapy, Victoria, Australia. 5 Monash Health, Monash Lung (...) , Belgium email@example.com. PMID: 32444407 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract The development of contractile muscle fatigue (CMF) affects training responses in patients with chronicobstructivepulmonarydisease (COPD). Downhill walking induces CMF with lower dyspnoea and fatigue than level walking. This study compared the effect of pulmonary rehabilitation (PR) comprising downhill walking training (DT) to PR comprising level walking
Randomized Trial of Nocturnal Oxygen in ChronicObstructivePulmonaryDisease. Long-term oxygen therapy improves survival in patients with chronicobstructivepulmonarydisease (COPD) and chronic severe daytime hypoxemia. However, the efficacy of oxygen therapy for the management of isolated nocturnal hypoxemia is uncertain.We designed this double-blind, placebo-controlled, randomized trial to determine, in patients with COPD who have nocturnal arterial oxygen desaturation without qualifying (...) for long-term oxygen therapy, whether nocturnal oxygen provided for a period of 3 to 4 years would decrease mortality or the worsening of disease such that patients meet current specifications for long-term oxygen therapy. Patients with an oxygen saturation of less than 90% for at least 30% of the recording time on nocturnal oximetry were assigned, in a 1:1 ratio, to receive either nocturnal oxygen or ambient air from a sham concentrator (placebo). The primary outcome was a composite of death from any
to the clinical effectiveness of the technology. Further information about how the evidence for this briefing was selected is available on request by contacting firstname.lastname@example.org. Published evidence Published evidence Three studies are summarised in this briefing, including 2 randomised controlled trials and 1 observational study. In total, there were 167 people with chronicobstructivepulmonarydisease (COPD) in these studies. The clinical evidence and its strengths and limitations is summarised (...) myCOPD for self-management of chronicobstructivepulmonarydisease myCOPD for self-management of chronicobstructivepulmonarydisease Medtech innovation briefing Published: 1 April 2020 www.nice.org.uk/guidance/mib214 pathways Summary Summary • The technology technology described in this briefing is myCOPD. It helps people with chronicobstructivepulmonarydisease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals
Proton pump inhibitors for chronicobstructivepulmonarydisease. Chronicobstructivepulmonarydisease (COPD) is a common and progressive disease characterised by chronic cough, airflowlimitation and recurrent exacerbations. Since COPD exacerbations are linked to rising mortality and reduced quality of life, the condition poses a substantial burden on individuals, society and the healthcare system. Effective management of COPD exacerbations that includes treatment of related conditions (...) COPD exacerbations, pneumonia and other serious adverse events. Secondary outcomes were quality of life, lung function test indices, acute respiratory infections and disease-specific adverse events. We extracted data on these outcome measures and entered into them into Review Manager software for analysis.The search identified 99 records, and we included one multicentre RCT that randomised 103 adults with COPD. The 12-month RCT compared an oral PPI (lansoprazole) and usual care versus usual care
ChronicObstructivePulmonaryDisease. Chronicobstructivepulmonarydisease (COPD) is characterized by persistent respiratory symptoms and progressive airflowobstruction. Tobacco smoking is the leading cause but not the only one. A postbronchodilator FEV1-FVC ratio less than 0.70 is required for a diagnosis of COPD. Inhaler therapy is the backbone of treatment and should be complemented by a multifaceted management strategy that includes counseling and pharmacotherapy for smoking cessation (...) , pulmonary rehabilitation, treatment of comorbidities, administration of influenza and pneumococcal immunizations, and prescription of long-term oxygen therapy in hypoxemic patients.
Chronicobstructivepulmonarydisease (COPD) is associated with a higher level of serum uric acid. A systematic review and meta-analysis Chronicobstructivepulmonarydisease (COPD) is associated with a higher level of serum uric acid. A systematic review and meta-analysis | Wattanachayakul | Advances in Respiratory Medicine MENU Shortcuts Open Journal Systems open access Vol 88, No 3 (2020) Research paper Published online: 2020-07-18 Submitted: 2019-12-28 Accepted: 2020-03-15 Get Citation BIB (...) with chronicobstructivepulmonarydisease (COPD) may have a higher level of serum uric acid compared with individuals without COPD, although the data are still limited. The current systematic review and meta-analysis was conducted to summarize all available data. Material and methods: A systematic review was performed using the MEDLINE and EMBASE databases from their inception to July 2019. Studies that were eligible for the meta-analysis must have consisted of two groups of participants, patients